Objective: To study the differences of metabolites in different metabolic pathways of serum tryptophan in patients with diabetic kidney disease (DKD) and healthy controls, and analyze the correlation between differential metabolites and clinical indicators. Method: Taking patients in the Nephrology Department and Endocrinology Department of the First Affiliated Hospital of Baotou Medical College as the research objects, 10 DKD patients were selected as the disease study group, and 10 healthy subjects were selected as the normal control group, and blood samples were collected. The differences of serum tryptophan and its metabolites in the two groups were analyzed by targeted metabolomics method, and then biological information analysis and statistical analysis were performed to clarify its significance in DKD. Results: Five differential metabolites were identified in the serum of DKD patients and healthy controls. The levels of L-tryptophan (L-TRP) and serotonin (5-HT) in serum of DKD patients were significantly lower than those of healthy controls,the difference was statistically significant (P＜0.05).While the levels of 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), and 3-indolepropionic acid (IPA) are increased, the difference was also statistically significant(P＜0.05). There was a significant positive correlation between 5-HIAA and IPA with serum creatinine, and a significant negative correlation with glomerular filtration rate. Conclusions: Serum tryptophan metabolite levels in DKD patients were significantly different from those in healthy controls, and some of the differential metabolites are also significantly correlated with the occurrence and development of DKD.
SU Ling
,
MI Yan
,
WANG Caili
. Targeted study of serum tryptophan metabolic profile in patients with diabetic kidney disease[J]. Journal of Baotou Medical College, 2023
, 39(4)
: 7
-12
.
DOI: 10.16833/j.cnki.jbmc.2023.04.002
[1] Hasegawa S, Inagi R. Harnessing metabolomics to describe the pathophysiology underlying progression in diabetic kidney disease[J]. Curr Diab Rep, 2021,21(7):21.
[2] Liu Y, Chen XF, Liu Y, et al. Metabolomic study of the protective effect of Gandi capsule for diabetic nephropathy[J]. Chem Biol Interact, 2019,314:108815.
[3] Chou CA, Lin CN, Chiu DTY, et al. Tryptophan as a surrogate prognostic marker for diabetic nephropathy[J]. J Diabetes Investig, 2018,9(2):366-374.
[4] Debnath S, Velagapudi C, Redus L, et al. Tryptophan metabolism in patients with chronic kidney disease secondary to type 2 diabetes: relationship to inflammatory markers[J].Int J Tryptophan Res, 2017,10:517489800.
[5] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 国际内分泌代谢杂志,2021,41(4):388-410.
[6] Brown KL, Darris C, Rose KL,et al. Hypohalous acids contribute to renal extracellular matrix damage in experimental diabetes[J].Diabetes, 2015,64(6):2242-2253.
[7] Zhang Y, Ruan YZ, Zhang P, et al. Increased indoleamine 2, 3-dioxygenase activity in type 2 diabetic nephropathy[J]. J Diabetes Complications, 2017,31(1):223-227.
[8] Brown J, Robusto B, Morel L. Intestinal dysbiosis and tryptophan metabolism in autoimmunity[J]. Front Immunol, 2020,11:1741.
[9] Hara K, Hirowatari Y, Shimura Y, et al. Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease[J]. Diabetes Res Clin Pract, 2011,94(2):167-171.
[10] Fukui M, Shiraishi E, Tanaka M, et al. Plasma serotonin is a predictor for deterioration of urinary albumin excretion in men with type 2 diabetes mellitus[J]. Metabolism, 2009,58(8):1076-1079.
[11] Saito J, Suzuki E, Tajima Y, et al. Increased plasma serotonin metabolite 5-hydroxyindole acetic acid concentrations are associated with impaired systolic and late diastolic forward flows during cardiac cycle and elevated resistive index at popliteal artery and renal insufficiency in type 2 diabetic patients with microalbuminuria[J]. Endocr J, 2016,63(1):69-76.
[12] De Mello VD, Paananen J, Lindström J, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study[J]. Sci Rep, 2017,7:46337.
[13] Tuomainen M, Lindström J, Lehtonen M, et al. Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals[J]. Nutr Diabetes, 2018,8(1):35.
[14] Tan YM, Gao Y, Teo G, et al. Plasma metabolome and lipidome associations with type 2 diabetes and diabetic nephropathy[J]. Metabolites, 2021,11(4):228.
